Chronic Thromboembolic Pulmonary Hypertension: Diagnosis and Treatment
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a severe and complex condition characterized by persistent pulmonary hypertension resulting from unresolved pulmonary embolism. It is classified as Group 4 pulmonary hypertension and can lead to significant right heart failure if left untreated [1]. While considered a rare complication of acute pulmonary embolism (APE), its true incidence may be underestimated due to underdiagnosis [1, 2].
Pathophysiology
CTEPH involves a multifaceted disease process extending beyond simple mechanical obstruction. It is characterized by the fibrotic obstruction of pulmonary arteries, which can affect both proximal (lobar-to-segmental) and distal (subsegmental) vessels. Additionally, pulmonary microvasculopathy, similar to that seen in pulmonary arterial hypertension, contributes to increased pulmonary vascular resistance and progressive right heart dysfunction [1, 2]. The exact mechanisms by which residual clots persist and undergo fibrotic transformation are not fully understood, but various risk factors, including certain chronic medical conditions and thrombophilia, have been identified [1].
Diagnosis
A high index of suspicion is crucial for timely diagnosis, especially in patients with unexplained dyspnea or persistent symptoms after an APE [1]. Initial screening often involves echocardiography and ventilation-perfusion (V/Q) scans. A mismatched V/Q scan in the presence of suspected pulmonary hypertension should prompt further investigation. Confirmatory diagnosis and assessment of hemodynamic severity require right heart catheterization (RHC) [1, 2]. Multimodal imaging, including computed tomography pulmonary angiography (CTPA) and conventional pulmonary angiography (CPA), is essential to characterize the location and extent of the thromboembolic burden and guide treatment decisions [1]. The rarity of the disease and non-specific symptoms often pose barriers to early diagnosis [1].
Treatment Strategies
The management of CTEPH is complex and requires a multidisciplinary approach involving PEA surgeons, interventionalists, and pulmonary hypertension specialists [1, 2]. The cornerstone of treatment for operable patients is **Pulmonary Endarterectomy (PEA)**, a surgical procedure aimed at removing organized fibrotic material from the pulmonary arteries. PEA is considered potentially curative and significantly improves patient outcomes [1, 2]. Patient selection for PEA is meticulous, considering factors such as symptom severity, degree of pulmonary hypertension, location of obstructions, and overall patient health [1].
For patients deemed inoperable due to distal disease, severe comorbidities, or personal preference, or for those with persistent/recurrent pulmonary hypertension after PEA, alternative therapies are available. **Balloon Pulmonary Angioplasty (BPA)** is an interventional procedure that can improve hemodynamics and symptoms by dilating obstructed pulmonary arteries [1, 2]. Additionally, targeted **pharmacological treatments** play a vital role. These include PDE5 inhibitors, endothelin receptor antagonists, and sGC stimulators, which help reduce pulmonary vascular resistance [1]. Lifelong anticoagulation is also a critical component of management to prevent recurrent thromboembolism [1].
Conclusion
Chronic Thromboembolic Pulmonary Hypertension is a serious but treatable condition. Early recognition, accurate diagnosis through comprehensive imaging and hemodynamic assessment, and a tailored, multidisciplinary therapeutic strategy are paramount to improving patient outcomes. Advances in surgical techniques, interventional procedures, and medical therapies offer hope for patients with this challenging disease.
References
[1] Simeone, B., et al. (2024). Chronic Thromboembolic Pulmonary Hypertension: the therapeutic assessment. *Frontiers in Cardiovascular Medicine*, 11, 1439411. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11337617/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337617/) [2] Cazeiro, D. I., et al. (2025). Chronic thromboembolic pulmonary hypertension: A comprehensive review of pathogenesis, diagnosis, and treatment strategies. *Revista Portuguesa de Cardiologia*, 44(2), 121-137. [https://www.sciencedirect.com/science/article/pii/S0870255124001872](https://www.sciencedirect.com/science/article/pii/S0870255124001872)